An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Autoimmune Disorders
|
Systemic Lupus Erythematosus, Lupus Nephritis |
Phase 1, Phase 2 |
Spain |
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
|
Chronic Spontaneous Urticaria |
Phase 3 |
Spain France United StatesGermany Korea, Republic of View All |
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
|
Polymyalgia Rheumatica |
Phase 3 |
Australia United States Switzerland |
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
|
Pulmonary Arterial Hypertension |
Phase 2 |
Germany Poland |
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
|
Hypercholesterolemia |
Phase 3 |
United States |
A Randomized Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis
|
Psoriasis |
Not Applicable |
Korea, Republic of |
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
|
Hepatic Impairment |
Phase 1 |
Hungary |
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
|
Primary Prevention of Atherosclerotic Cardiovascular Disease |
Phase 3 |
United States Canada Hong KongAustralia View All |
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
|
Breast Cancer |
|
France |
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies
|
Heterozygous or Homozygous Familial Hypercholesterolemia |
Phase 3 |
Netherlands United States SwitzerlandRussian Federation Slovenia Norway Spain Hungary View All |